

June 24, 2016

The Honorable Jeff King, Chairperson
Senate Committee on Judiciary
Statehouse, Room 341-E
Topeka, Kansas 66612

Dear Senator King:

SUBJECT: Fiscal Note for SB 2 by Senate Committee on Judiciary

In accordance with KSA 75-3715a, the following fiscal note concerning SB 2 is respectfully submitted to your committee.

SB 2 would add the synthetic opioid, 3,4-dichloro-N-[2-(demethylamino) cyclohexyl]-N-methylbenzamide, commonly referred to as U-47700, to the list of controlled substances included in Schedule 1 of the Controlled Substances Act that is administered by the Kansas State Board of Pharmacy. The bill would take effect upon publication in the statute book.

The passage of SB 2 would have no fiscal effect for the Kansas State Board of Pharmacy.

Sincerely,



Shawn Sullivan,
Director of the Budget

cc: Alexandra Blasi, Board of Pharmacy